Evidence map›Paper›PMID 30327887›Full record

ArticlePharmaceutical research2018

Improving Plasma Stability and Bioavailability In Vivo of Gemcitabine Via Nanoparticles of mPEG-PLG-GEM Complexed with Calcium Phosphate.

Wei Chu, Pengqian Tian, Ning Ding, Qing Cai, Jinlong Li, Xuezhi Zhuo, Zhaohui Tang, Jingxin Gou, Tian Yin, Yu Zhang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Wei ChuDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Pengqian TianDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Ning DingDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Qing CaiDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Jinlong LiDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Xuezhi ZhuoDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Zhaohui TangKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, People's Republic of China.
Jingxin GouDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Tian YinDepartment of Functional food and Wine, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Yu ZhangDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Haibing HeDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Xing TangDepartment of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China. tanglab@126.com.ORCID http://orcid.org/0000-0001-5313-9901
Shenyang Pharmaceutical University · CNChinese Academy of Sciences · CN

Funding

China Postdoctoral Science Foundation 2016M600216
6 · The paper itself

Abstract

purposeDespite being widely used for the treatment of several solid tumors, Gemcitabine (GEM) exhibits several suboptimal pharmacokinetic properties. Therefore, the design of nanoparticle delivery systems is a promising strategy to enhance GEM pharmacokinetic properties.

methodsIn this work, the polymeric material methoxy poly(ethylene glycol)-block-poly(L-glutamic acid)-graft-gemcitabine (mPEG-b-PLG-g-GEM) was synthesized through the covalent conjugation of GEM with the carboxylic group of methoxy poly(ethylene glycol)-block-poly (L-glutamic acid) (mPEG-b-PLG) (mPEG

resultsAfter incubation in plasma at 37°C for 24 h, gemcitabine was degraded by 24.6% for the mPEG-PLG-GEM, 14.7% for the mPEG-PLG-GEM/CaP nanoparticles, and 90% for the free gemcitabine solution. It was observed that mPEG-PLG-GEM and mPEG-PLG-GEM/CaP improved the area-under-curve (AUC) values by 5.26-fold and 6.33-fold compared to free drug, respectively.

conclusionThe amide bond linked gemcitabine polymers was able to protect GEM from cytidine deaminase degradation in vivo, and the skeleton formed by the calcium phosphate enhanced the stability and prolonged the half-life of GEM. Importantly, mPEG-PLG-GEM/CaP nanoparticles elevated the GEM plasma concentration in an animal model.

Indexed as

AnimalsAntimetabolites, AntineoplasticCalcium PhosphatesDeoxycytidineDrug StabilityGemcitabineHumansNanoconjugatesPolyethylene GlycolsPolyglutamic AcidRats, Sprague-DawleyAntimetabolites, Antineoplasticcalcium phosphateCalcium PhosphatesDeoxycytidineGemcitabinemethoxypoly(ethylene glycol)-block-poly(glutamic acid)NanoconjugatesPolyethylene GlycolsPolyglutamic Acidcalcium phosphatenanoparticlespharmacokineticspolyethylene glycol-poly glutamic acid-gemcitabinestability

Identifiers

PMID30327887
OpenAlexW2897008664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.